Syncom Formulations (India) enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


1,911	—	—	—	—
112	112	89.9	127	63.1
1.5	1.5	4.6	72.5	83.2
1,801	—	—	—	—
−110	−110	−85.3	−54.6	20.0
₹19.16	—	—	—	—

416	416	347	361	339
0.4%	0.4%	1.3%	20.1%	24.5%
0.00×	—	—	—	—

3.62×	—	—	—	—
20.50×	—	—	—	—
22.21×	—	—	—	—
38.80×	—	—	—	—
498	489	465	263	224
87.8	77.4	54.1	29.6	19.6
81.1	70.9	48.9	24.9	15.1
—	58.1	23.4	−6.0	10.5
46.4	46.4	13.5	−14.1	−10.1
—	46.1	13.3	−15.2	−10.9
—	11.7	10.0	8.1	20.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health

₹ CrorePeersHESTERBIO NGLFINE WINDLAS JAGSNPHARMAMRUTANJAN INDOCO SAIPARENTMcap ₹1,911 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,911.0
- Cash, Equiv & ST Investments	63.1	127.1	89.9	111.7	111.7
+ Total Debt	83.2	72.5	4.6	1.5	1.5
Enterprise Value	—	—	—	—	1,800.8
Net Debt (memo)	20.0	-54.6	-85.3	-110.2	-110.2
EV per Share	—	—	—	—	19.16

Total Capital	339.2	360.6	346.7	416.5	416.5
Total Debt/Total Capital	24.52	20.10	1.32	0.35	0.35
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	3.62
EV/EBITDA	—	—	—	—	20.50
EV/EBIT	—	—	—	—	22.21
EV/Free Cash Flow	—	—	—	—	38.80
Reference Items — Trailing FY Values
Sales	224.3	263.4	465.0	489.2	497.8
EBITDA	19.6	29.6	54.1	77.4	87.8
EBIT	15.1	24.9	48.9	70.9	81.1
Operating Cash Flow	10.5	-6.0	23.4	58.1	—
Free Cash Flow	-10.1	-14.1	13.5	46.4	46.4
FCFF (free cash flow to the firm)	-10.9	-15.2	13.3	46.1	—
Capital Expenditure	20.6	8.1	10.0	11.7	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.